3-m-bromoacetylamino benzoic acid ethyl ester: A new cancericidal agent that activates the apoptotic pathway through caspase-9

Biochemical Pharmacology

Volumn 60, Issue 11, 2000, Pages 1693-1702

  Schlesinger, Michael ^a,b   Jiang, Jian Dong ^a,c   Roboz, Julia P ^a   Denner, Larry ^d   Ling, Yi He ^e   Holland, James F ^a   Bekesi, J George ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b HEBREW UNIVERSITY   (Israel)

^c INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^d TEXAS BIOTECHNOLOGY CORPORATION   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cancericidal drug; Caspases

Indexed keywords

3 BROMOACETYLAMINO BENZOIC ACID ETHYL ESTER; ANTINEOPLASTIC AGENT; ASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BENZOIC ACID DERIVATIVE; CASPASE; CASPASE 3; CASPASE 3 INHIBITOR; CASPASE 6; CASPASE 6 INHIBITOR; CASPASE 8; CASPASE 8 INHIBITOR; CASPASE 9; CASPASE 9 INHIBITOR; CASPASE INHIBITOR; DNA FRAGMENT; ISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; LEUCYLGLUTAMYLHISTIDYLASPARTYL FLUOROMETHYL KETONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; UNCLASSIFIED DRUG; VALYLGLUTAMYLISOLEUCYLASPARTYL FLUOROMETHYL KETONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; KIDNEY CANCER; LEUKEMIA CELL LINE; LYMPHOMA CELL LINE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOIC ACID; BENZOIC ACIDS; CASPASE 9; CASPASES; CELL CYCLE; DNA FRAGMENTATION; ESTERS; HUMANS; MICE; MICROTUBULES; POLY(ADP-RIBOSE) POLYMERASES; TUMOR CELLS, CULTURED;

EID: 0034571322     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00484-6     Document Type: Article

References (35)

1. Apoptosis in cancer therapy crossing the threshold
2. Apoptosis induced by anticancer drugs
3. Caspases: The executioners of apoptosis
4. BCL-2 gene family and the regulation of programmed cell death
5. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents
6. Double identity for proteins of the Bcl-2 family
7. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation
8. Apaf 1 is required for mitochondrial pathways of apoptosis and brain development
9. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis
10. The Bcl-xL and Bax-α control points: Modulation of apotosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation
11. Insights from Bcl-2 and Myc: Malignancy involves abrogation of apoptosis as well as sustained proliferation
12. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax: Bcl-2 ratio
13. The Baxα: Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia
14. Inactivation of Bcl-2 by phosphorylation
15. Bcl2 is the guardian of microtubule integrity
16. Death receptors: Signaling and modulation
17. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53
18. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells
19. Inhibition of microtubule assembly in tumor cells by 3-bromoacetylamino benzoylurea, a new cancericidal compound
20. 3-(Iodoacetamido)-benzoylurea: A novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells
21. Novel suicide ligands of tubulin arrest cancer cells in S-phase
22. Synthesis, cancericidal and antimicrotubule activities of 3-(haloacetamido)-benzoylureas
23. Translocation of cytoplasmic antigen markers in a biphenotypic cell line derived from a patient with myelodysplastic syndrome
24. Retrovirus-mediated transfer of anti-MDR1 ribozymes fully restores chemosensitivity of P-glycoprotein-expressing human lymphoma cells
25. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for prostate cancer
26. Pleiotropic drug resistance and survival advantage in leukemic cells with diminished apoptotic response
27. The drug efflux protein P-glycoprotein additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis
28. Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells
29. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis
30. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex
31. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally
32. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apopototic protease cascade
33. Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner
34. Apaf 1 is required for mitochondrial pathways of apoptosis and brain development
35. Differential requirement for caspase 9 in apoptotic pathways in vivo